Recent Updates
Recently added Catalysts
HURA

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

Tuesday, February 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
Price reaction · baseline $1.33 (2026-02-13 close) · hit after-hours · clean, no other HURA news in the window
day 0 close
-15%
day 1 · peak
-15.4%
day 3
-13.5%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+457%
120-day peak, hindsight
Typical move
7%
average across 2 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
dalazatide
Phase 1 · Plaque Psoriasis

Full Press Release Details

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers.
ShareAdd on Google
Tags: HURA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Feb 17, 2026

Biotech snapshot

Cash runway
$1M liquidity · $3M/mo burn
~0 mo
High dilution risk
Lead asset
dalazatidePhase 1
Plaque Psoriasis →

Catalyst track record

+457%
best trade around HURA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for HURA.

See every catalyst's timing & PoA →